Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 777-784

  Liu, Tiancheng ^a   Wu, Lisa Y ^a   Choi, Joseph K ^a   Berkman, Clifford E ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Cancer Targeted Technology   (United States)

Author keywords

Apoptosis; Caspase 8; Prostate cancer

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; FLUORESCENCE; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; CHLOROPHYLL; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; MALE; MICROSCOPY, CONFOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77749261698     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000553     Document Type: Article

References (34)

1. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ and Sibata CH: Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther 1: 27-42, 2004.
2. Sharman WM, van Lier JE and Allen CM: Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56: 53-76, 2004.
3. Detty MR, Gibson SL and Wagner SJ: Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 47: 3897-3915, 2004.
4. Berg K, Selbo PK, Weyergang A, et al: Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 218: 133-147, 2005.
5. Liu T, Wu LY, Kazak M and Berkman CE: Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68: 955-964, 2008.
6. Liu T, Wu LY, Choi JK and Berkman CE: In vitro targeted photodynamic therapy with a pyropheophorbide - a conjugated inhibitor of prostate-specific membrane antigen. Prostate 69: 585-594, 2009.
7. Murphy GP, Su S, Jarisch J and Kenny GM: Serum levels of PSMA. Prostate 42: 318-319, 2000.
8. Bacich DJ, Pinto JT, Tong WP and Heston WD: Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/ NAALADase/folate hydrolase. Mamm Genome 12: 117-123, 2001.
9. Fair WR, Israeli RS and Heston WD: Prostate-specific membrane antigen. Prostate 32: 140-148, 1997.
10. Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776: 86-107, 2007
11. Olivo M and Ali-Seyed M: Apoptosis signalling mechanisms in human cancer cells induced by Calphostin-PDT. Int J Oncol 30: 537-548, 2007.
12. Ali SM, Chee SK, Yuen GY and Olivo M: Hypericin induced death receptor-mediated apoptosis in photoactivated tumor cells. Int J Mol Med 9: 601-616, 2002.
13. Ali SM, Chee SK, Yuen GY and Olivo M: Photodynamic therapy induced Fas-mediated apoptosis in human carcinoma cells. Int J Mol Med 9: 257-270, 2002.
14. Moor AC: Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B 57: 1-13, 2000.
15. Morgan J and Oseroff AR: Mitochondria-based photodynamic anti-cancer therapy. Adv Drug Deliv Rev 49: 71-86, 2001.
16. Wu LY, Anderson MO, Toriyabe Y, et al: The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 15: 7434-7443, 2007.
17. Maung J, Mallari JP, Girtsman TA, et al: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 12: 4969-4979, 2004.
18. Anderson MO, Wu LY, Santiago NM, et al: Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 15: 6678-6686, 2007.
19. Liu T, Toriyabe Y and Berkman CE: Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 49: 251-255, 2006.
20. Furre IE, Moller MT, Shahzidi S, Nesland JM and Peng Q: Involvement of both caspase-dependent and -independent pathways in apoptotic induction by hexaminolevulinate-mediated photodynamic therapy in human lymphoma cells. Apoptosis 11: 2031-2042, 2006.
21. Agostinis P, Buytaert E, Breyssens H and Hendrickx N: Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci 3: 721-729, 2004.
22. Tian Y, Leung W, Yue K and Mak N: Cell death induced by MPPa-PDT in prostate carcinoma in vitro and in vivo. Biochem Biophys Res Commun 348: 413-420, 2006.
23. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 20: 4070-4084, 2001.
24. Liu T, Toriyabe Y, Kazak M and Berkman CE: Pseudo-irreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 47: 12658-12660, 2008.
25. Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES and Paulsen KD: Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 65: 6371-6379, 2005.
26. Sun X and Leung WN: Photodynamic therapy with pyropheophorbide-a methyl ester in human lung carcinoma cancer cell: efficacy, localization and apoptosis. Photochem Photobiol 75: 644-651, 2002.
27. Benchoua A, Couriaud C, Guegan C, et al: Active caspase-8 translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) polymerase-2. J Biol Chem 277: 34217-34222, 2002.
28. Raz V, Carlotti F, Vermolen BJ, et al: Changes in lamina structure are followed by spatial reorganization of heterochromatic regions in caspase-8-activated human mesenchymal stem cells. J Cell Sci 119: 4247-4256, 2006.
29. Decker P and Muller S: Modulating poly(ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3: 275-283, 2002.
30. Mashima T, Naito M, Noguchi K, Miller DK, Nicholson DW and Tsuruo T: Actin cleavage by CPP-32/apopain during the development of apoptosis. Oncogene 14: 1007-1012, 1997.
31. Mashima T, Naito M and Tsuruo T: Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis. Oncogene 18: 2423-2430, 1999.
32. Takahashi H, Itoh Y, Miyauchi Y, et al: Activation of two caspase cascades, caspase-8/3/6 and caspase-9/3/6, during photodynamic therapy using a novel photosensitizer, ATX-S10(Na), in normal human keratinocytes. Arch Dermatol Res 295: 242-248, 2003.
33. Lee TJ, Um HJ, Min do S, Park JW, Choi KS and Kwon TK: Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 46: 1639-1649, 2009.
34. Schempp CM, Simon-Haarhaus B, Termeer CC and Simon JC: Hypericin photo-induced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8. FEBS Lett 493: 26-30, 2001.